Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P35609

UPID:
ACTN2_HUMAN

ALTERNATIVE NAMES:
Alpha-actinin skeletal muscle isoform 2; F-actin cross-linking protein

ALTERNATIVE UPACC:
P35609; B1ANE4; B2RCS5; Q86TF4; Q86TI8

BACKGROUND:
Alpha-actinin-2 functions as a key F-actin cross-linking protein, essential for the stabilization of actin filaments and the organization of the sarcomere in muscle cells. Its alternative names include Alpha-actinin skeletal muscle isoform 2 and F-actin cross-linking protein, highlighting its significance in muscle physiology.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Alpha-actinin-2 could open doors to potential therapeutic strategies. Given its involvement in various myopathies and cardiomyopathies, targeting Alpha-actinin-2 related pathways may offer novel approaches for treating these debilitating conditions, emphasizing the importance of further research into its functions and disease associations.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.